Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Tyra Biosciences, Inc. Common Stock

TYRA

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Last trade $19.54
Day change -$0.20 (-1.01%)
Day range $19.34 – $20.65
Volume 469,620
Market cap $1.36B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.36B
Price / earnings
—
Price / book
1.97×
Price / sales
—
EV / sales
—
EV / EBITDA
-4.99×

Profitability

Earnings per share
-$2.45
Return on assets
-23.3%
Return on equity
-24.46%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
23.93×
Quick ratio
23.93×
Cash ratio
15.33×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$119.78M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TYRA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$11.74M$9.81M$8.53M$8.33M$7.48M$7.14M$6.89M$7.56M
Research and development$43.14M$39.2M$33.47M$28.19M$25.47M$24.31M$24.96M$22.18M
Total operating expenses$54.89M$49M$42M$36.52M$32.94M$31.45M$31.85M$29.74M
Operating income-$54.89M-$49M-$42M-$36.52M-$32.94M-$31.45M-$31.85M-$29.74M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$51.12M-$45.56M-$39.31M-$33.83M-$29.87M-$28.1M-$28.15M-$25.57M
Income taxes$0$0$0$0$0$0$0$0
Net income-$51.12M-$45.56M-$39.31M-$33.83M-$29.87M-$28.1M-$28.15M-$25.57M
Net income attributable to common shareholders-$51.12M-$45.56M-$39.31M-$33.51M-$29.87M-$28.1M-$28.15M-$26.94M
EBITDA-$54.76M-$48.87M-$41.86M-$36.38M-$32.81M-$31.31M-$31.71M-$29.6M
Basic earnings per share-$0.74-$0.69-$0.64-$0.56-$0.50-$0.47-$0.47-$0.46
Diluted earnings per share-$0.74-$0.69-$0.64-$0.56-$0.50-$0.47-$0.47-$0.46

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

Pomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences following the company's announcement of Phase 2 SURF302 study results for oral dabogratinib. Despite claims of a favorable safety profile, the study showed 14% and 9% of participants experienced Grade 3 adverse events in the 60mg and 50mg dose cohorts respectively. The announcement triggered a 17.66% stock price decline on September 9, 2026.

The Motley Fool

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinical-stage investments.

The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake

Commodore Capital completely exited its 3.2 million share position in Viridian Therapeutics (worth $69 million) on February 17, 2026, reducing the holding from 3.4% of the fund's assets to zero. This comes despite Viridian's stock being up 75% over the past year and entering a catalyst-heavy 2026 with FDA approval decisions and Phase 3 data expected. The exit suggests the fund may be taking profits after the strong rally or reallocating capital to other clinical-stage biotech names.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.